
Xiaohua Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2532607/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The ETNK2 gene promotes progression of papillary thyroid carcinoma through the HIPPO pathway. Journal of Cancer, 2022, 13, 508-516.	2.5	1
2	Identification of a Pyroptosis-Related Prognostic Signature Combined With Experiments in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2022, 9, 822503.	3.5	10
3	Glucose-to-Lymphocyte Ratio (GLR) as a Predictor of Preoperative Central Lymph Node Metastasis in Papillary Thyroid Cancer Patients With Type 2 Diabetes Mellitus and Construction of the Nomogram. Frontiers in Endocrinology, 2022, 13, 829009.	3.5	3
4	Downstream Neighbor of Son Overexpression is Associated With Breast Cancer Progression and a Poor Prognosis. Journal of Breast Cancer, 2022, 25, 327.	1.9	3
5	Identification and validation of L Antigen Family Member 3 as an immune-related biomarker associated with the progression of papillary thyroid cancer. International Immunopharmacology, 2021, 90, 107267.	3.8	9
6	Development and Validation of a Nomogram for Preoperative Prediction of Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma and Type 2 Diabetes Mellitus. Cancer Management and Research, 2021, Volume 13, 2499-2513.	1.9	0
7	LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt/β‑catenin signaling pathway and epithelial‑mesenchymal transition. Oncology Letters, 2021, 21, 442.	1.8	7
8	Genomic Instability-Related LncRNA Signature Predicts the Prognosis and Highlights LINC01614 Is a Tumor Microenvironment-Related Oncogenic IncRNA of Papillary Thyroid Carcinoma. Frontiers in Oncology, 2021, 11, 737867.	2.8	8
9	Major Vault Protein (MVP) Associated With BRAFV600E Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer via MAPK/ERK and PI3K/AKT Pathways. Frontiers in Cell and Developmental Biology, 2021, 9, 688370.	3.7	5
10	The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery. Cancer Management and Research, 2020, Volume 12, 8875-8886.	1.9	2
11	Identification of the prognostic and immunotherapeutic potential of L antigen family member 3 in malignant pleural mesothelioma. Clinical and Translational Medicine, 2020, 10, e207.	4.0	5
12	Subcutaneous Recurrences of Thyroid Cancer After Conventional Transcervical Thyroidectomy: A Case Report. Frontiers in Surgery, 2020, 7, 586106.	1.4	2
13	Downregulating integrin subunit alpha 7 (ITGA7) promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition. Acta Biochimica Et Biophysica Sinica, 2020, 52, 116-124.	2.0	10
14	Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. Frontiers in Oncology, 2020, 10, 592811.	2.8	10
15	Up-regulation of L Antigen Family Member 3 Associates With Aggressive Progression of Breast Cancer. Frontiers in Oncology, 2020, 10, 553628.	2.8	3
16	Upregulation of LAGE3 correlates with prognosis and immune infiltrates in colorectal cancer: A bioinformatic analysis. International Immunopharmacology, 2020, 85, 106599.	3.8	17
17	T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAFV600E Mutation in Papillary Thyroid Carcinoma. Frontiers in Cell and Developmental Biology, 2020, 8, 590898.	3.7	4
18	CUX2 functions as an oncogene in papillary thyroid cancer. OncoTargets and Therapy, 2019, Volume 12, 217-224.	2.0	7

XIAOHUA ZHANG

#	Article	lF	CITATIONS
19	KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation. Cancer Medicine, 2019, 8, 3544-3552.	2.8	21
20	Uridine phosphorylase 1 associates to biological and clinical significance in thyroid carcinoma cell lines. Journal of Cellular and Molecular Medicine, 2019, 23, 7438-7448.	3.6	15
21	Original tumour suppressor gene polycystic kidney and hepatic disease 1‑like 1 is associated with thyroid cancer cell progression. Oncology Letters, 2019, 18, 3227-3235.	1.8	13
22	H/ACA box small nucleolar RNA 7B acts as an oncogene and a potential prognostic biomarker in breast cancer. Cancer Cell International, 2019, 19, 125.	4.1	20
23	<p>Lipase member H is a downstream molecular target of hypoxia inducible factor-1α and promotes papillary thyroid carcinoma cell migration in BCPAP and KTC-1 cell lines</p> . Cancer Management and Research, 2019, Volume 11, 931-941.	1.9	10
24	Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer. OncoTargets and Therapy, 2019, Volume 12, 9707-9713.	2.0	7
25	Alantolactone promotes ER stressâ€mediated apoptosis by inhibition of TrxR1 in tripleâ€negative breast cancer cell lines and in a mouse model. Journal of Cellular and Molecular Medicine, 2019, 23, 2194-2206.	3.6	28
26	METTL7B promotes migration and invasion in thyroid cancer through epithelial-mesenchymal transition. Journal of Molecular Endocrinology, 2019, 63, 51-61.	2.5	34
27	Osthole inhibits triple negative breast cancer cells by suppressing STAT3. Journal of Experimental and Clinical Cancer Research, 2018, 37, 322.	8.6	50
28	TEKT4 Promotes Papillary Thyroid Cancer Cell Proliferation, Colony Formation, and Metastasis through Activating PI3K/Akt Pathway. Endocrine Pathology, 2018, 29, 310-316.	9.0	18
29	Clinicopathological characteristics and prognostic factors for primary thyroid lymphoma: report on 28 Chinese patients and results of a population-based study. Cancer Management and Research, 2018, Volume 10, 4411-4419.	1.9	8
30	A mono-carbonyl analog of curcumin induces apoptosis in drug-resistant EGFR-mutant lung cancer through the generation of oxidative stress and mitochondrial dysfunction. Cancer Management and Research, 2018, Volume 10, 3069-3082.	1.9	18
31	Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3. Toxicology and Applied Pharmacology, 2018, 358, 110-119.	2.8	31
32	MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines. Biochemical and Biophysical Research Communications, 2018, 504, 434-439.	2.1	34
33	ITGA7 functions as a tumor suppressor and regulates migration and invasion in breast cancer. Cancer Management and Research, 2018, Volume 10, 969-976.	1.9	32
34	Synaptopodin-2 plays an important role in the metastasis of breast cancer via PI3K/Akt/mTOR pathway. Cancer Management and Research, 2018, Volume 10, 1575-1583.	1.9	17
35	LRP4 promotes proliferation, migration, and invasion in papillary thyroid cancer. Biochemical and Biophysical Research Communications, 2018, 503, 257-263.	2.1	20
36	Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 327-339.	2.2	3

XIAOHUA ZHANG

#	Article	IF	CITATIONS
37	Curcuminoid EF24 enhances the antiâ€tumour activity of Akt inhibitor MKâ€2206 through ROSâ€mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer. British Journal of Pharmacology, 2017, 174, 1131-1146.	5.4	42
38	ZCCHC12, a novel oncogene in papillary thyroid cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1679-1686.	2.5	15
39	GABRB2 plays an important role in the lymph node metastasis of papillary thyroid cancer. Biochemical and Biophysical Research Communications, 2017, 492, 323-330.	2.1	21
40	Silencing of semaphorin 3C suppresses cell proliferation and migration in MCFâ€′7 breast cancer cells. Oncology Letters, 2017, 14, 5913-5917.	1.8	14
41	(S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. Journal of Experimental and Clinical Cancer Research, 2017, 36, 120.	8.6	27
42	Treatment patterns and patient profiles for docetaxel-based adjuvant chemotherapy in early-stage breast cancer in China: A pooled analysis of four observational studies Journal of Clinical Oncology, 2017, 35, e12017-e12017.	1.6	0
43	<i>BRAF</i> and <i>TERT</i> promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget, 2016, 7, 18346-18355.	1.8	109
44	Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics. OncoTargets and Therapy, 2016, 9, 761.	2.0	79
45	Preoperative endoscopic localization of colorectal cancer and tracing lymph nodes by using carbon nanoparticles in laparoscopy. World Journal of Surgical Oncology, 2016, 14, 231.	1.9	25
46	miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumor Biology, 2016, 37, 6837-6845.	1.8	47
47	β3-tubulin is a good predictor of sensitivity to taxane-based neoadjuvant chemotherapy in primary breast cancer. Clinical and Experimental Medicine, 2016, 16, 391-397.	3.6	3
48	Prediction of central lymph node metastasis in 392 patients with cervical lymph node-negative papillary thyroid carcinoma in Eastern China. Oncology Letters, 2015, 10, 2559-2564.	1.8	16
49	Papillary thyroid microcarcinoma with synchronous asymptomatic advanced esophageal squamous cell carcinoma: A case report and review of the literature. Oncology Letters, 2015, 9, 731-734.	1.8	3
50	The use of OK-432 to prevent seroma in extended latissimus dorsi flap donor site after breast reconstruction. Journal of Surgical Research, 2015, 193, 492-496.	1.6	12
51	The Utility of Sentinel Lymph Node Biopsy in Papillary Thyroid Carcinoma with Occult Lymph Nodes. PLoS ONE, 2015, 10, e0129304.	2.5	16